Citations

Clear

6728 citation(s) found for "Li, Mark".

Actin Mutations in Dilated Cardiomyopathy, a Heritable Form of Heart Failure
Olson, Timothy M. , Michels, Virginia V., Thibodeau, Stephen N. , Tai, Yin-Shan, Keating, Mark T., Olson, Timothy M

Mayo Clinic

Science | July 27, 2002 | Volume: 280 | Issue: 5364 | Pages: 750-752

10.1126/science.280.5364.750 | PMID 9563954 Get It

To test the hypothesis that actin dysfunction leads to heart failure, patients with hereditary idiopathic dilated cardiomyopathy (IDC) were examined for mutations in the cardiac actin gene ( ACTC ). Missense mutations in ACTC that cosegregate with IDC were identified in two unrelated families. Both mutations affect universally conserved amino acids in domains of actin that attach to Z bands and intercalated discs. Coupled with previous data showing that dystrophin mutations also cause dilated cardiomyopathy, these results raise the possibility that defective transmission of force in cardiac myocytes is a mechanism underlying heart failure.
Role of Dynamin in the Formation of Transport Vesicles from the Trans-Golgi Network
Jones, Steven M. , Howell, Kathryn E., Henley, John R. , Cao, Hong , McNiven, Mark A.

Mayo Clinic

Science | July 27, 2002 | Volume: 279 | Issue: 5350 | Pages: 573-577

10.1126/science.279.5350.573 | PMID 9438853 Get It

Dynamin guanosine triphosphatases support the scission of clathrin-coated vesicles from the plasmalemma during endocytosis. By fluorescence microscopy of cultured rat hepatocytes, a green fluorescent protein–dynamin II fusion protein localized with clathrin-coated vesicles at the Golgi complex. A cell-free assay was utilized to demonstrate the role of dynamin in vesicle formation at the trans-Golgi. Addition of peptide-specific anti-dynamin antibodies to the assay mixture inhibited both constitutive exocytic and clathrin-coated vesicle formation. Immunodepletion of dynamin proteins also inhibited vesicle formation, and budding efficiency was restored upon readdition of purified dynamin. These data suggest that dynamin participates in the formation of distinct transport vesicles from the trans-Golgi network.
Comparison of Mechanical Properties of Various Suture Repair Techniques in a Partially Lacerated Tendon
Zobitz, Mark E., Zhao, Chunfeng , Amadio, Peter C. , An, Kai‐Nan

Mayo Clinic

Journal of Biomechanical Engineering | July 27, 2002 | Volume: 122 | Issue: 6 | Pages: 604-607

10.1115/1.1324668 | PMID 11192381 Get It

The technique of surgical repair for zone two flexor tendon injuries has been debated extensively throughout the years, yet adhesion formation, suture rupture, and suture locking on the pulley edge remain possible consequences of a poor repair. The partially lacerated tendon is especially challenging to treat since there can be justification for not intervening surgically. In a partial laceration canine model we measured failure load and suture gap formation for tendons repaired with the Lee, modified four-strand Savage, Kessler, modified Kessler, and Augmented Becker core suture techniques and with a simple running peripheral suture. The modified Kessler (106.3 N, SD 18.8 N) and modified Savage (108.2 N, SD 19.9 N) repair techniques had a significantly higher failure load than the Lee (85.0 N, SD 20.6 N) suture method p<0.05, while there were no differences among the other techniques. There were no significant differences in resistance to gap formation among the repair techniques, with the mean values ranging from 38.9 N/mm (SD 15.7 N/mm) using the simple running suture to 53.2 N/mm (SD 25.8 N/mm) with the Kessler repair. The mean load to produce a 1.5 mm repair site gap ranged from 71.1 N (SD 21.5 N) in the Lee repair to 91.3 N (SD 22.2 N) in the Augmented Becker repair although there were no significant differences among repair methods. All repair methods were much weaker than tendons left unrepaired (184.7 N, SD 41.3 N). [S0148-0731(00)00706-8]
Effects of the Bcr/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro
Mow, Benjamin, Svingen, Phyllis A., Hallgren, Christopher G., Kottke, Timothy, Narayanan, V. L. , Litzow, Mark R. , Griffin, James D. , Sausville, Edward A., Tefferi, Ayalew , Chandra, Joya , Weisberg, Ellen , Kaufmann, Scott H.

Mayo Clinic

Blood | July 27, 2002 | Volume: 99 | Issue: 2 | Pages: 664-671

10.1182/blood.v99.2.664 | PMID 11781252 Get It

Abstract The adenosine triphosphate binding-site–directed agent STI571 and the tyrphostin adaphostin are undergoing evaluation as bcr/abl kinase inhibitors. The current study compared the effects of these agents on the survival of K562 cells, bcr/abl-transduced FDC-P1 cells, and myeloid progenitors from patients with chronic myelogenous leukemia (CML) compared with healthy donors. Treatment of K562 cells with 10 μM adaphostin resulted in decreased p210bcr/ablpolypeptide levels in the first 6 hours, followed by caspase activation and accumulation of apoptotic cells in less than 12 hours. By 24 hours, 90% of the cells were apoptotic and unable to form colonies. In contrast, 20 μM STI571 caused rapid inhibition of bcr/abl autophosphorylation without p210bcr/abl degradation. Although this was followed by the inhibition of Stat5 phosphorylation and the down-regulation of Bcl-xL and Mcl-1, only 7% ± 3% and 25% ± 9% of cells were apoptotic at 16 and 24 hours, respectively. Instead, the cytotoxic effects of STI571 became more pronounced with prolonged exposure, with IC90values greater than 20 μM and 1.0 ± 0.6 μM after 24 and 48 hours, respectively. Consistent with these results, 24-hour adaphostin exposure inhibited CML granulocyte colony-forming units (CFU-G) (median IC50, 12 μM) but not normal CFU-G (median IC50, greater than 20 μM), whereas 24-hour STI571 treatment had no effect on CML or normal CFU-G. Additional experiments revealed that STI571-resistant K562 cells remained sensitive to adaphostin. Moreover, the combination of STI571 + adaphostin induced more cytotoxicity in K562 cells and in CML CFU-G than either agent alone did. Collectively, these results identify adaphostin as a mechanistically distinct CML-selective agent that retains activity in STI571-resistant cell lines.
Multiple Sclerosis
Noseworthy, John H., Keegan, B. Mark

Mayo Clinic

Annual Review of Medicine | July 27, 2002 | Volume: 53 | Issue: 1 | Pages: 285-302

10.1146/annurev.med.53.082901.103909 | PMID 11818475 Get It

▪ Abstract Multiple sclerosis (MS) is a common inflammatory disease of the central nervous system (CNS). Diagnosis rests upon identifying typical clinical symptoms and interpreting supportive laboratory and radiological investigations. The etiology is unknown; however, strong evidence suggests that MS is an autoimmune disease directed against CNS myelin or oligodendrocytes. Genetic factors are important in the development of MS. Contributing environmental determinants (possibly including infectious agents) appear important but remain unidentified. Both cell-mediated and humorally mediated immune mechanisms contribute to pathological injury. Axonal damage occurs in addition to demyelination and may be the cause of later permanent disability. Distinct pathological subtypes may differentiate among patients with MS. Treatment is directed at acute attacks (with corticosteroids) and reduction of attack frequency (primarily with type-1 β interferons and glatiramer acetate). Research into the causes and treatments of MS has expanded our knowledge of this disease and promises improved care for MS patients in the future.
Valganciclovir Results in Improved Oral Absorption of Ganciclovir in Liver Transplant Recipients
Pescovitz, Mark D., Rabkin, John M. , Merion, Robert M. , Payá, Carlos V., Pirsch, John D., Freeman, Richard B. , O'Grady, John, Robinson, Charles A., To, Zung, Wren, Kristina, Banken, Ludger, Buhles, William, Brown, Frances C., O’Grady, John

Mayo Clinic

Antimicrobial Agents and Chemotherapy | July 27, 2002 | Volume: 44 | Issue: 10 | Pages: 2811-2815

10.1128/aac.44.10.2811-2815.2000 | PMID 10991864 Get It

ABSTRACT The pharmacokinetics of an orally administered valine ester of ganciclovir (GCV), valganciclovir (VGC), were studied. These were compared to the pharmacokinetics of oral and intravenous GCV. Twenty-eight liver transplant recipients received, in an open-label random order with a 3- to 7-day washout, each of the following: 1 g of oral GCV three times a day; 450 mg of VGC per os (p.o.) once a day (q.d.); 900 mg of VGC p.o. q.d.; and 5 mg of intravenous (i.v.) GCV per kg of body weight q.d., given over 1 h. GCV and VGC concentrations were measured in blood over 24 h. One-sided equivalence testing was performed to test for noninferiority of 450 mg of VGC relative to oral GCV (two-sided 90% confidence interval [CI] > 80%) and nonsuperiority of 900 mg of VGC relative to i.v. GCV (two-sided 90% CI < 125%). The exposure of 450 mg of VGC (20.56 μg · h/ml) was found to be noninferior to that of oral GCV (20.15 μg · h/ml; 90% CI for relative bioavailability of 95 to 109%), and the exposure of 900 mg of VGC (42.69 μg · h/ml) was found to be nonsuperior to that of i.v. GCV (47.61 μg · h/ml; 90% CI = 83 to 97%). Oral VGC delivers systemic GCV exposure equivalent to that of standard oral GCV (at 450 mg) or i.v. GCV (at 900 mg of VGC). VGC has promise for effective CMV prophylaxis or treatment with once-daily oral dosing in transplant recipients.
Determination of the Compressive Material Properties of the Supraspinatus Tendon
Zobitz, Mark E., Luo, Zong‐Ping , An, Kai‐Nan

Mayo Clinic

Journal of Biomechanical Engineering | July 27, 2002 | Volume: 123 | Issue: 1 | Pages: 47-51

10.1115/1.1339816 | PMID 11277301 Get It

A methodology was developed for determining the compressive properties of the supraspinatus tendon, based on finite element principles. Simplified three-dimensional models were created based on anatomical thickness measurements of unloaded supraspinatus tendons over 15 points. The tendon material was characterized as a composite structure of longitudinally arranged collagen fibers within an extrafibrillar matrix. The matrix was formulated as a hyperelastic material described by the Ogden form of the strain energy potential. The hyperelastic material parameters were parametrically manipulated until the analytical load-displacement results were similar to the results obtained from indentation testing. In the geometrically averaged tendon, the average ratio of experimental to theoretical maximum indentation displacement was 1.00 (SD: 0.01). The average normalization of residuals was 2.1g (SD: 0.9g). Therefore, the compressive material properties of the supraspinatus tendon extrafibrillar matrix were adequately derived with a first-order hyperelastic formulation. The initial compressive elastic modulus ranged from 0.024 to 0.090 MPa over the tendon surface and increased nonlinearly with additional compression. Using these material properties, the stresses induced during acromional impingement can be analyzed.
Fatal Pulmonary Toxicity Related to the Administration of Granulocyte Colony-Stimulating Factor in Amyloidosis: A Report and Review of Growth Factor-Induced Pulmonary Toxicity
Lacy, Martha Q. , Björnsson, Jóhannes, Litzow, Mark R. , Gertz, Morie A.

Mayo Clinic

Journal of Hematotherapy & Stem Cell Research | July 26, 2002 | Volume: 9 | Issue: 5 | Pages: 635-643

10.1089/15258160050196678 | PMID 11091487 Get It

Papillary Renal Cell Carcinoma: Analysis of Germline Mutations in the MET Proto-Oncogene in a Clinic-Based Population
Lindor, Noralane M. , Dechet, Christopher , Greene, Mark H. , Jenkins, Robert B. , Zincke, M. Tanja, Weaver, Amy L. , Wilson, Marcia, Zincke, Horst, Liu, Wanguo

Mayo Clinic

Genetic Testing | July 26, 2002 | Volume: 5 | Issue: 2 | Pages: 101-106

10.1089/109065701753145547 | PMID 11551094 Get It

Melanocyte Destruction after Antigen-Specific Immunotherapy of Melanoma
Yee, Cassian , Thompson, John A. , Roche, Patrick C. , Byrd, David R. , Lee, Peter P. , Piepkorn, Michael W., Kenyon, Karla, Riddell, Stanley R. , Davis, Mark M. , Greenberg, Philip D.

Mayo Clinic

The Journal of Experimental Medicine | July 26, 2002 | Volume: 192 | Issue: 11 | Pages: 1637-1644

10.1084/jem.192.11.1637 | PMID 11104805 Get It

Current strategies for the immunotherapy of melanoma include augmentation of the immune response to tumor antigens represented by melanosomal proteins such as tyrosinase, gp100, and MART-1. The possibility that intentional targeting of tumor antigens representing normal proteins can result in autoimmune toxicity has been postulated but never demonstrated previously in humans. In this study, we describe a patient with metastatic melanoma who developed inflammatory lesions circumscribing pigmented areas of skin after an infusion of MART-1–specific CD8+ T cell clones. Analysis of the infiltrating lymphocytes in skin and tumor biopsies using T cell–specific peptide–major histocompatibility complex tetramers demonstrated a localized predominance of MART-1–specific CD8+ T cells (&gt;28% of all CD8 T cells) that was identical to the infused clones (as confirmed by sequencing of the complementarity-determining region 3). In contrast to skin biopsies obtained from the patient before T cell infusion, postinfusion biopsies demonstrated loss of MART-1 expression, evidence of melanocyte damage, and the complete absence of melanocytes in affected regions of the skin. This study provides, for the first time, direct evidence in humans that antigen-specific immunotherapy can target not only antigen-positive tumor cells in vivo but also normal tissues expressing the shared tumor antigen.